Background/Aims: Published studies indicated that the MTHFR gene polymorphisms C677T and A1298C are associated with congenital heart disease (CHD) risk in children, but obtained inconsistent results. Our study aims to reach a more accurate association between these two polymorphisms and CHD risk. Methods: Eligible studies were obtained by screening the PubMed, Embase, China National Knowledge Infrastructure, Wan Fang and VIP databases based on designed searching strategy. The odds ratio (OR) and 95% confidence interval (CI) were calculated. Moreover, a trial sequential analysis was introduced to confirm the positive results and an RNA secondary structure analysis was also applied to discover the potential molecular mechanism. Results: Based on thirty-two published articles, involving 6988 congenital heart disease subjects and 7579 healthy controls, the pooled results from the C677T polymorphism in the fetal population showed increased risks in allelic model (OR=1.32, 95%CI=1.14-1.53), recessive model (OR=1.69, 95%CI=1.25-2.30), dominant model (OR=1.35, 95%CI=1.11-1.64), heterozygote model (OR=1.20, 95%CI=1.01-1.41) and homozygote model (OR=1.75, 95%CI=1.31-2.33). An increased risk was only detected in the A1298C polymorphism in the overall fetal popalation in a recessive model (OR=1.42, 95%CI=1.10-1.84). In the subgroup stratified by region, sample size, genotyping method and source of controls, the increased risks were widely observed in both the C677T and A1298C polymorphisms with CHD risk. Furthermore, trial sequential analysis confirmed our positive results, and the RNA secondary structure analysis detected the changes in the RNA secondary structure caused by the mutant 677T allele and 1298C allele. Conclusion: In summary, we found that the MTHFR C677T polymorphism is associated with a significant increased risk in congenital heart disease
Introduction
Congenital heart disease (CHD) is the most frequently occurring congenital disorder in newborns and the most common type of structural malformation of the heart and lager blood vessels [1, 2] . The aetiology of CHD is unclear and CHD is multifactorial in its derivation. Different related genes interacting with each other or with environmental factors may contribute to development of CHD [3] . Folate plays a crucial role in the ontogeny of the cardiovascular system [4] . Insufficient folic acid and a high level of homocysteine (Hcy) caused by a defective folic acid pathway are described as risk factors for CHD [5] . Therefore, common polymorphisms of folate-metabolizing enzymes have gained great attention.
The MTHFR gene, located on 1p36.3, encodes the vital enzyme involved in the folate/ homocysteine metabolic pathway. Its transcription product is a 77 kDa protein, that catalyses the reduction of 5, 10-methylenetetrahydrofolate to 5-methytetrahydrofolate, which as a methyl donor induces Hcy remethylation to methionine [6] . Two common functional polymorphisms in the MTHFR gene are widely studied. The first one is the MTHFR C677T mutation at exon 4, which results in the conversion of the amino acid alanine to valine at position 226 in the protein [6] . The other mutation (MTHFR A1298C) is located at exon 7, within the presumptive regulatory domain, and results in a glutamate-to-alanine change with decreased enzyme activity in vitro [7] .
Associations between these two MTHFR gene polymorphisms and CHD risk were firstly analyzed by Wenstrom et al. [8] ., more and more studies were conducted to perfect this work in the recent years. However, previous case-control reports or meta-analyses have drawn inconsistent results and many biases exist in these studies. Therefore, we performed an updated meta-analysis to investigate the associations between MTHFR polymorphisms (C677T and A1298C) and the susceptibility to CHD. Moreover, a trial sequential analysis and a RNA secondary structure analysis were introduced in our meta-analysis to confirm our positive results and identify the potential possible mechanism respectively.
Materials and Methods
Based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) checklist [9] , we organized our update meta-analysis. Ethical approval was not necessary for the type of the study (meta-analysis) [10] .
Identification of related Studies
A literature search was conducted by the first two investigators in the PubMed, Embase, China National Knowledge Infrastructure, Wan Fang and VIP databases before August 2017 without a language limitation. The terms "MTHFR," "methylenetetrahydrofolate reductase," "congenital heart disease," "CHD," "ventricular septal defect," "atrial septal defect," "tetralogy of Fallot," "patent ductus arteriosus," "polymorphism," "variant," "mutant," and "polymorphisms" were used. The data that we failed to retrieve during the electronic search were obtained by reviewing the citations or contacting the corresponding author of the potential eligible articles.
Inclusion and Exclusion criteria
The included studies needed to meet the following inclusion criteria: (1) studies of the association between the MTHFR gene polymorphisms and congenital heart disease; (2) case-control study or cohort design in fetal population; and (3) detailed genotype data could be acquired to calculate the odds ratios (ORs), and 95% confidence intervals (CIs); The exclusion criteria were as follows: (1) 
Data Extraction
From each study, the following data were independently extracted by the first two investigators using a standardized form: first author's last name; year of publication; study country; region; genotyping methods; source of controls; number of cases and controls; genotype frequency in the cases and controls for the MTHFR gene; and results of the Hardy-Weinberg equilibrium test. Disagreements were resolved through a group discussion between authors.
Statistical analysis
The Hardy-Weinberg equilibrium (HWE) was evaluated for each study by a Chi-square test in the control group, and P < 0.05 was considered a significant departure from HWE. The odds ratio (OR) and 95% confidence intervals (CIs) were calculated among five genetic models (allelic model (C677T: C versus T; A1298C: A versus C), recessive model (C677T: TT versus TC+CC; A1298C: CC versus CA+AA), dominant model (C677T: TT+TC versus CC; A1298C: CC+CA versus AA), heterozygote model (C677T: TC versus CC; A1298C: CA versus AA), and homozygote model (C677T: TT versus CC; A1298C: CC versus AA), respectively). Heterogeneity was evaluated by the Q statistic (significance level of P < 0.1) and I 2 statistic (greater than 50% as evidence of significant inconsistency). A sensitivity analysis was performed to detect the heterogeneity by omitting one study in each turn. Additionally, subgroup analyses were stratified by region, sample size, genotyping method and source of controls. The publication bias was assessed with a Begg's funnel plot and an Egg's test. Review Manager, Version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration; Copenhagen, Denmark) and STATA 12.0 (STATA Corp, LP) was used for all the analyses. Multiple comparisons were adjusted by the Bonferroni method and the false discovery rate (FDR) was calculated [11] . The statistically significant level was determined by a Z-test with P value less than 0.05.
Trial sequential analysis (TSA)
TSA (The Copenhagen Trial Unit, Center for Clinical Intervention Research, Denmark) is a methodology that combines an information size calculation (cumulated sample sizes of all included trials) to reduce type I errors and type II errors for a meta-analysis with the threshold of statistical significance (http://www. ctu.dk/tsa). Therefore, we introduced TSA into our meta-analysis, and the required information size was calculated in adhere to an overall type I error of 5%, a power of 90% and a relative risk reduction (RRR) assumption of 10%.
RNA secondary structure analysis
The RNAfold WebServer is one of the core programs of the Vienna RNA package (http://rna.tbi.univie. ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi) [12] , which can be used to predict secondary structures of single stranded RNA or RNA sequences by computing the minimum free energy (MFE) of single sequences based on the dynamic programming algorithm originally proposed by Zuker and Stiegler [13] . Therefore, we input the RNA sequence of the MTHFR C677T and A1298C polymorphisms into the RNAfold WebServer to analyse the potential secondary structure modification caused by the mutant allele.
Results

Characteristics of the Included Studies
One hundred and fifty-one articles were obtained by the online and manual search. After removing duplicates, screening the title and abstract and reading the full-text articles, forty-two articles were included in the qualitative synthesis, and then, nine articles were excluded for departure from the Hardy Weinberg Equilibrium. Finally, a total of thirty-three published articles [4, involving 6988 cases and 7579 controls, were included in this meta-analysis (Fig. 1) .
The characteristics of all the included articles are summarized in Table 1 . For the C677T variant, thirty-two studies are included with 4848 cases and 5524 controls, and twelve studies with 2140 cases and 2055 controls, were included for the A1298C variant.
Results of the meta-analysis of the associations between MTHFR polymorphisms and congenital heart disease risk. Table 2 shows the pooled results of this meta-analysis and the heterogeneity of the MTHFR gene polymorphisms and congenital heart disease risk.
For the C677T polymorphism, significant associations were observed in all the genetic models in the overall population but with high heterogeneity as follows: T versus C (OR=1.32, 95%CI=1.14-1. 53 (Fig. 2) . However, when an adjusted p value test was conducted, the heterozygote model (TC VS CC) was a false positive. In addition, for the A1298C polymorphism, a significant association was only found in the recessive genetic model in the overall population (CC versus CA+AA: OR=1.42, 95%CI=1.10-1.84, P=0.008) (Fig.  3) . 
Subgroup analysis
To excavate the potential associations and underlying heterogeneity source from the pooled results, a subgroup analysis was performed and four subgroups (Region, Sample size, Genotyping method and source of controls) were stratified (Table 3) .
In the subgroup analysis of Region, significant associations were found for these two polymorphisms. In the Middle Europe subgroup, the allelic genetic model (OR=1.63, 95% In the subgroup analysis of Sample size, for the C677T polymorphism, wide significant associations with reduced heterogeneity were observed in the no more than 300 subgroup as follows: the allelic genetic model (OR=1.32, 95% CI=1.08-1.80, P=0.006); the dominant genetic model (OR=1.35, 95% CI=1.01-1.80, P=0.04); the recessive genetic model (OR=2.41, 95% CI=1.81-3.21, P=0.000); and the homozygote genetic model (OR=1.91, 95% CI=1.36-2.67, P=0.0002)). As for more than 300 subgroup, the allelic genetic model (OR=1.34, 95% CI=1.10-1.64, P=0.004), dominant genetic model (OR=1.36, 95% CI=1.06-1.76, P=0.02) and homozygote genetic model (OR=1.73, 95% CI=1.17-2.56, P=0.006) were associated with CHD risk. However, for the A1298C polymorphism, a significant association with reduced heterogeneity was only detected in the recessive genetic model (OR=2.05, 95% CI=1.02-4.10, P=0.04) in the no more than 300 subgroup.
As for the subgroup analysis stratified by the genotyping method, extensive significant associations were found in the C677T polymorphism by PCR-RFLP for the allelic genetic model (OR=1. 
Sensitivity analyses
The sensitivity analysis was conducted by sequentially omitting 1 individual study every time to weigh the influence of each study on the overall meta-analysis. No significant change in the heterogeneity was observed for these two polymorphisms (Fig. 4) .
Publication bias
No publication bias was detected among the studies regarding the association between the C677T and A1298C polymorphism and congenital heart defect risk (Fig. 5) .
Trial sequential analysis
According to the settings mentioned in the method section, we calculated the required information size for the MTHFR C677T and A1298C polymorphisms (Fig. 6) . The number of patients included in the meta-analysis exceeded the required information size for the two polymorphisms, which indicated our positive results were confirmed by TSA.
RNA secondary structure analysis
We conducted an RNA secondary structure analysis of the MTHFR C677T and A1298C polymorphisms with the RNAfold Webserver. Fig. 7 shows the significant changes in the RNA structure under both the minimum free energy and the centroid secondary structure, which indicated the two variants might affect the stability of the RNA secondary structure.
Discussion
The methylenetetrahydrofolate reductase (MTHFR) is the crucial enzyme concatenating the folate pathway and homocysteine metabolism [46] . Low folate and high homocysteine are a closely related with the occurrence of congenital heart disease [5, 47] , which indicates that single nucleotide polymorphisms (SNPs) in the MTHFR gene may be genetic risk factors for these disorders. The MTHFR C677T and A1298C SNPs are common and functional, with enough data for us to perform a subgroup analysis and a trial sequential analysis. Moreover, the mutant 677T and 1298C alleles are related to the decreased activity of the MTHFR enzyme [48] . Therefore, we chose these two polymorphisms to investigate their associations with CHD risk and significant increased risks were widely observed in both the overall and subgroup analyses.
An increased risk of CHD was detected in the MTHFR C677T polymorphism from the overall analysis. The putative risk allele-677T had a 32% increased risk of CHD risk against the C-allele. A 35% increase in CHD risk in the TT+TC genotypes was also detected. The TC and TT genotypes increased CHD risk by 20% and 75% compared to the CC genotype respectively. In addition, a 69% increased risk was also found in the TT genotypes compared to TC+CC genotypes. Moreover, the increased risk of the T allele, TT, TC and TT+TC genotypes was widely observed in the subgroup analysis stratified by region, sample size, genotyping method and source of controls. Furthermore, the TSA test confirmed our positive results. The extensive increased risk of the C677T polymorphism in CHD implied this polymorphism was a strong genetic risk factor for fetal heart defects.
As for the MTHFR A1298C polymorphism, the increased risk of the CC genotype was widely detected both from the pooled analysis and the subgroup analysis (West Asian subgroup, no more than 300 subgroup, PCR-GeXP subgroup and hospital-based subgroup), and the positive result was verified by TSA. Interesting results sprouted in the North Europe [49] [50] [51] . In summary, the CC genotype of the MTHFR A1298C polymorphism had an increased risk of CHD, but the protective role of 1298C allele should be interpreted with caution. Previous meta-analysises have also drawn a conclusion showing a significant association between the MTHFR polymorphism and CHD [52] [53] [54] [55] [56] [57] . The differences between our analysis and the former analyses was the sample size and the exclusion of studies with departure from the Hardy-Weinberg equilibrium. We added new references to expand the sample size for better reaching the significant results. Moreover, studies with departure from the Hardy-Weinberg equilibrium were excluded for homogeneity in the control groups, which would make our results more reliable and stable. Additionally, a trial sequential analysis was conducted to strengthen our positive results. Furthermore, the MTHFR C677T polymorphism was highly associated with homocysteine concentrations in the large scale, methodologically independent genome-wide association study [58] . However, no genome-wide association study about the A1298C polymorphism is reported so far.
Reduced MTHFR enzyme activity decreases the synthesis of 5-methyl-tetrahydrofolate (the substrate vital for DNA synthase), interrupts the homocysteine remethylation to methionine (a decreased pool of which may affect DNA methylation), and induces hyperhomocysteinemia [45] . Hyperhomocysteinemia initiates apoptosis in neural crest cells and has embryotoxic effects in heart cells in animal models [59, 60] . Although the MTHFR C677T and A1298C polymorphisms both diminish MTHFR enzyme activity, they act in different ways. The 677T variant causes a thermolabile form of the enzyme and is associated with elevated homocysteine levels, but for 1298C, it reduced the enzyme activity by conformational changes of the enzyme that occur after S-adenosyl-methionine regulatory domain binding [61, 62] . Our RNA secondary structure analysis showed that the mutant 677T and 1298C alleles changed the space conformation of the RNA secondary structure of the MTHFR gene and influenced the stability of this gene, which may be an explanation for the termolabile form of enzyme caused by the 677T allele and the conformational changes of the enzyme induced by the 1298C allele.
Several limitations were existed in this meta-analysis. First, only English and Chinese databases were searched in our study; a selection of the literature without other language may bias the results. Second, the individual patient heterogeneity and confounding factors might have distorted the analysis. Third, the sample size of the included studies was relatively small in some subgroups, especially for the A1298C polymorphism, which implied that part of our results should be explained with caution. In addition, the potential influence of maternal environment factors on these two polymorphisms is worthy of consideration.
Conclusion
The MTHFR C677T polymorphism was associated with a significant increase in congenital heart defect risk in the fetal population based on our analysis. Moreover, the increased risk in the CC genotype of the MTHFR A1298C polymorphism was observed, but the protective role of the 1298C allele needs further study.
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